Link between cognitive polygenic risk scores and clinical progression after a first-psychotic episode.

Abstract

BACKGROUND:

Clinical intervention in early stages of psychotic disorders is crucial for the prevention of severe symptomatology trajectories and poor outcomes. Genetic variability is studied as a promising modulator of prognosis, thus novel approaches considering the polygenic nature of these complex phenotypes are required to unravel the mechanisms underlying the early progression of the disorder.

METHODS:

The sample comprised of 233 first-episode psychosis (FEP) subjects with clinical and cognitive data assessed periodically for a 2-year period and 150 matched controls. Polygenic risk scores (PRSs) for schizophrenia, bipolar disorder, depression, education attainment and cognitive performance were used to assess the genetic risk of FEP and to characterize their association with premorbid, baseline and progression of clinical and cognitive status.

RESULTS:

Schizophrenia, bipolar disorder and cognitive performance PRSs were associated with an increased risk of FEP [false discovery rate (FDR) ⩽ 0.027]. In FEP patients, increased cognitive PRSs were found for FEP patients with more cognitive reserve (FDR ⩽ 0.037). PRSs reflecting a genetic liability for improved cognition were associated with a better course of symptoms, functionality and working memory (FDR ⩽ 0.039). Moreover, the PRS of depression was associated with a worse trajectory of the executive function and the general cognitive status (FDR ⩽ 0.001).

CONCLUSIONS:

Our study provides novel evidence of the polygenic bases of psychosis and its clinical manifestation in its first stage. The consistent effect of cognitive PRSs on the early clinical progression suggests that the mechanisms underlying the psychotic episode and its severity could be partially independent.

• Authors: Alex G Segura, Gisela Mezquida, Albert Martínez-Pinteño, Patricia Gassó, Natalia Rodriguez, Lucía Moreno-Izco, Silvia Amoretti, Miquel Bioque, Antonio Lobo, Ana González-Pinto, Alicia García-Alcon, Alexandra Roldán-Bejarano, Eduard Vieta, Elena de la Serna, Alba Toll, Manuel J Cuesta, Sergi Mas, Miquel Bernardo, PEPs Group
• Journal: Psychological medicine (Psychol Med) Vol. 53 Issue 10 Pg. 4634-4647 (07 2023) ISSN: 1469-8978 [Electronic] England
• PMID: 35678455 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Topics

• Humans
• Psychotic Disorders
• Schizophrenia (drug therapy)
• Risk Factors
• Disease Progression
• Cognition